Neurocysticercosis in travelers: A nation-wide study in IsraelArchived
Cysticercosis is the infection by the larval form of Taenia solium. The authors describe 9 cases of neurocysticercosis - diagnosed in Israeli travellers during a period of 15 years.
Eyal Leshem, Iris Kliers, Mati Bakon, Moshe Gomori, Rebekah Karplus and Eli Schwartz.J Travel Med. 2011 18 (3):191-197
Cysticercosis is the infection by the larval form of Taenia solium. The authors describe 9 cases of neurocysticercosis diagnosed in Israeli travellers during a period of 15 years. Patients had travelled to South and/or Asia. The most common symptom at diagnosis was a seizure. The average interval between return from the suspected travel and symptom onset was 3.2 ± 1.8 years.
ECDC comment: Neurocysticercosis is endemic in many resource-limited countries. In western countries, it is mostly encountered among immigrant populations but is rare in other travellers. This report reminds that food and water safety practices have to be reinforced in people planning to stay for long periods in endemic regions. A common misleading recommendation is pork avoidance, but it has no role in the prevention of this disease.
Extensively drug-resistant gonorrhoea: risk of further dissemination within and across Europe
1 Apr 2019 - ECDC comment on the study 'Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018' by Eyre et al. in the Eurosurveillance edition of 7 March 2019.
Conclusions of the twentieth IHR Emergency Committee do not change the ECDC risk assessment for Europe concerning polio
11 Mar 2019 - Statement of the twentieth IHR Emergency Committee Regarding the International Spread of Poliovirus, 1 March 2019
WHO recommendations for influenza virus vaccine composition for the 2019–2020 northern hemisphere season
1 Mar 2019 - On 18–20 February 2019, the World Health Organization (WHO) agreed on the recommended composition of the quadrivalent influenza vaccine for the northern hemisphere 2019–2020 influenza season: an A/Brisbane/02/2018 (H1N1)pdm09-like virus, an A(H3N2) virus component to be announced on 21 March 2019, a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage) and a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage).